MedTrace Logo

Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer

NCT02383251 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2023-09-06

No results posted yet for this study

Summary

Study of Pazopanib and weekly Paclitaxel in patients with platinum resistant/refractory ovarian cancer who relapse during bevacizumab maintenance.

Conditions

Interventions

DRUG

Pazopanib

Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg

DRUG

Paclitaxel

Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • ARCAGY/ GINECO GROUP

    lead OTHER

Principal Investigators

  • Florence JOLY, PHD · Centre François Baclesse, Caen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-15
Primary Completion
2019-08-31
Completion
2020-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02383251 on ClinicalTrials.gov